Intelligence Feed event · Equity · 2026-09-09

    Dentsply Sirona Beats Q2 EPS at $0.52 and Maintains FY26 Revenue Outlook

    Question

    Dentsply Sirona Beats Q2 EPS at $0.52 and Maintains FY26 Revenue Outlook

    Direct answer

    DENTSPLY SIRONA reported second-quarter adjusted EPS of $0.52, exceeding consensus expectations of $0.36 by 16 cents. Total net sales experienced a 4.1% year-over-year decline, though internal division performance showed strength in Wellspect Healthcare, which grew 7.1%. The company maintained its full-year 2026 revenue guidance range of $3.5 billion to $3.6 billion alongside an adjusted EPS target of $1.40 to $1.50, signaling stable full-year margin expectations despite quarterly top-line pressure.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Dentsply Sirona Beats Q2 EPS at $0.52 and Maintains FY26 Revenue Outlook”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-beats-q2-eps-at-0-52-and-maintains-fy26-revenue-outlook-9e91d3

    EQUITY
    Dentsply Sirona Beats Q2 EPS at $0.52 and Maintains FY26 Revenue Outlook
    DENTSPLY SIRONA reported second-quarter adjusted EPS of $0.52, exceeding consensus expectations of $0.36 by 16 cents. Total net sales experienced a 4.1% year-over-year decline, though internal division performance showed strength in Wellspect Healthcare, which grew 7.1%. The company maintained its full-year 2026 revenue guidance range of $3.5 billion to $3.6 billion alongside an adjusted EPS target of $1.40 to $1.50, signaling stable full-year margin expectations despite quarterly top-line pressure.
    XRAY
    Impact
    67
    SEP 9
    SIG
    92%
    XRAY
    Dentsply Sirona Beats Q2 EPS at $0.52 and Maintains FY26 Revenue Outlook
    DENTSPLY SIRONA reported second-quarter adjusted EPS of $0.52, exceeding consensus expectations of $0.36 by 16 cents. Total net sales experienced a 4.1% year-over-year decline, though internal division performance showed strength in Wellspect Healthcare, which grew 7.1%. The company maintained its full-year 2026 revenue guidance range of $3.5 billion to $3.6 billion alongside an adjusted EPS target of $1.40 to $1.50, signaling stable full-year margin expectations despite quarterly top-line pressure.
    → Cost controls and 7.1% Wellspect segment growth offset a 4.1% revenue decline, delivering a 16-cent Q2 adjusted EPS beat for XRAY.
    Impact
    DENTSPLY SIRONA reported second-quarter adjusted EPS of $0.52, exceeding consensus expectations of $0.36 by 16 cents. Total net sales experienced a 4.1% year-over-year decline, though internal division performance showed strength in Wellspect Healthcare, which grew 7.1%. The company maintained its full-year 2026 revenue guidance range of $3.5 billion to $3.6 billion alongside an adjusted EPS target of $1.40 to $1.50, signaling stable full-year margin expectations despite quarterly top-line pressure.
    Affected
    XRAY
    Transmission
    Cost controls and 7.1% Wellspect segment growth offset a 4.1% revenue decline, delivering a 16-cent Q2 adjusted EPS beat for XRAY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYcost containment EPS beat against top-line sales contractionMixed1-5dXRAY reported Q2 adjusted EPS of $0.52 vs $0.36 consensus while revenue fell 4.1%.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYMixed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month